The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance.
about
The relationship between sex hormones, sex hormone binding globulin and peripheral artery disease in older personsImpressive predictive value of ankle-brachial index for very long-term outcomes in patients with cardiovascular disease: IMPACT-ABI study.The Viborg Vascular (VIVA) screening trial of 65-74 year old men in the central region of Denmark: study protocolAbnormal joint powers before and after the onset of claudication symptoms.To screen or not to screen for peripheral arterial disease in subjects aged 80 and over in primary health care: a cross-sectional analysis from the BELFRAIL study.Cyclophilin A is associated with peripheral artery disease and chronic kidney disease in geriatrics: The Tianliao Old People (TOP) studyClot strength is negatively associated with ambulatory function in patients with peripheral artery disease and intermittent claudication.Optimal management of peripheral arterial disease for the non-specialistVariation in the use of lower extremity vascular procedures for critical limb ischemia.The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trialEffect of exercise training on clot strength in patients with peripheral artery disease and intermittent claudication: An ancillary studyImpaired Coronary Endothelial Vasorelaxation in a Preclinical Model of Peripheral Arterial InsufficiencySurgical infrainguinal revascularization for peripheral arterial disease: factors affecting patency rateABPI against Colour Duplex Scan: A Screening Tool for Detection of Peripheral Arterial Disease in Low Resource Setting Approach to Validation.Regional intensity of vascular care and lower extremity amputation ratesExercise training and peripheral arterial disease.Using risk models to improve patient selection for high-risk vascular surgery.Spinal cord stimulation for patients with inoperable chronic critical leg ischemia.Peripheral Artery Disease Prevalence and Incidence Estimated From Both Outpatient and Inpatient Settings Among Medicare Fee-for-Service Beneficiaries in the Atherosclerosis Risk in Communities (ARIC) StudyDisruption of mitochondrial quality control in peripheral artery disease: New therapeutic opportunities.Prolonged sitting leg vasculopathy: contributing factors and clinical implications.A Molecular and Clinical Review of Stem Cell Therapy in Critical Limb Ischemia.Microfibrillar-associated protein 4 variation in symptomatic peripheral artery disease.MiR-323b-5p acts as a novel diagnostic biomarker for critical limb ischemia in type 2 diabetic patients
P2860
Q33729775-07D4FC60-311F-4D34-93E5-95B0311A6227Q33803200-B1071C77-C36E-4CEE-A324-B2DBF27BCA5AQ33939428-F547E376-49BF-4AB6-842A-6DC6CB06A18DQ34066383-C42EEA12-57E8-4DA2-906F-A346EA469B6DQ35063654-AA4FA58D-DA9E-47C7-AA07-9DDCD239A38FQ35535488-C6FED7C2-F6D1-4AAC-B0B3-701111EAAA0FQ35555531-26F3A1B7-EA30-468C-955F-56B1141EFF93Q35761784-3B54BA81-21C5-4131-B83F-FF7CFE475E30Q35762765-416515EF-6829-489A-A296-EA2819432F1EQ36348650-BD7CBDFF-226C-4EFC-A932-D04FF02F5A47Q36372057-1AC44883-CB6E-40DA-971C-D7F216459377Q36418319-B4010A21-2AE5-4D35-9612-AE51126FD030Q36469420-D1FAC903-10D3-43CF-B02F-2B15903CB019Q36724641-D6381FFA-A6A4-4427-B12E-62A61B3C0ADAQ36864191-001D209E-C7DF-4F95-B935-DB46CD428DA6Q37157213-E9E25CAE-521C-4181-9213-F2191212C3DAQ37288327-E9F97013-9984-41F9-B4F1-587258B41B81Q38248599-BFFEF284-52C9-4BD4-B11D-1138D6A205A0Q38806511-80BE24BC-2FE1-4F7E-B604-8DAA824CBADEQ39017060-D8E6B6FB-5E6E-4759-91F1-68D52C5107F6Q39451382-11DA6EBD-2522-44A2-888A-FC894C5BC2CFQ48189678-1E2DA09B-439E-4BDF-882F-D6D3EA0C7C96Q55473994-0B91A008-F3C2-41A4-B191-189CC9E43787Q57286519-7C4C3B8C-9976-44ED-8C15-F2741D79DAF4
P2860
The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The magnitude of the problem o ...... ogy and clinical significance.
@ast
The magnitude of the problem o ...... ogy and clinical significance.
@en
type
label
The magnitude of the problem o ...... ogy and clinical significance.
@ast
The magnitude of the problem o ...... ogy and clinical significance.
@en
prefLabel
The magnitude of the problem o ...... ogy and clinical significance.
@ast
The magnitude of the problem o ...... ogy and clinical significance.
@en
P1476
The magnitude of the problem o ...... logy and clinical significance
@en
P2093
Mary McGrae McDermott
P356
10.3949/CCJM.73.SUPPL_4.S2
P478
73 Suppl 4
P577
2006-10-01T00:00:00Z